Indoxyl sulfate and high-density lipoprotein cholesterol in early stages of chronic kidney disease

References

• Go AS, Chertow GM, Fan D, et al. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296–1305.
   PubMed Web of Science ®Google Scholar
• Bueschkens DH, Stiles ME. Escherichia coli variants for gas and indole production at elevated incubation temperatures. Appl Environ Microbiol. 1984;48(3):601–605.
   PubMed Web of Science ®Google Scholar
• Barreto FC, Barreto DV, Liabeuf S, et al.; European Uremic Toxin Work Group (EUTox). Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol. 2009;4(10):1551–1558.
   PubMed Web of Science ®Google Scholar
• Zsom L, Faludi M, Fülöp T, et al. The association of overhydration with chronic inflammation in chronic maintenance hemodiafiltration patients. Hemodial Int. 2019;23(3):384–391.
   PubMed Web of Science ®Google Scholar
• Wu IW, Hsu KH, Lee CC, et al. p-Cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease. Nephrol Dial Transplant. 2011;26(3):938–947.
   PubMed Web of Science ®Google Scholar
• Cao X-S, Chen J, Zou J-Z, et al. Association of indoxyl sulfate with heart failure among patients on hemodialysis. CJASN. 2015;10(1):111–119.
   PubMed Web of Science ®Google Scholar
• Chen J, Zhang X, Ding X, et al. Indoxyl sulfate enhance the hypermethylation of klotho and promote the process of vascular calcification in chronic kidney disease. Int J Biol Sci. 2016;12(10):1236–1246.
   PubMed Web of Science ®Google Scholar
• Xiang F, Chen R, Cao X, et al. Monocyte/lymphocyte ratio as a better predictor of cardiovascular and all-cause mortality in hemodialysis patients: a prospective cohort study. Hemodialysis Inter. 2018;22(1):82–92.
   PubMed Web of Science ®Google Scholar
• Santos-Gallego CG, Badimon JJ, Rosenson RS. Beginning to understand high-density lipoproteins. Endocrinol Metab Clin North Am. 2014;43(4):913–947.
   PubMed Web of Science ®Google Scholar
• Reiss AB, Voloshyna I, De Leon J, et al. Cholesterol metabolism in CKD. Am J Kidney Dis. 2015;66(6):1071–1082.
   PubMed Web of Science ®Google Scholar
• Florens N, Calzada C, Lyasko E, et al. Modified lipids and lipoproteins in chronic kidney disease: a new class of uremic toxins. Toxins (Basel). 2016;8(12):376.
   PubMed Web of Science ®Google Scholar
• Vaziri ND. Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences. Kidney Int. 2016;90(1):41–52.
   PubMed Web of Science ®Google Scholar
• Keane WF, Tomassini JE, Neff DR. Lipid abnormalities in patients with chronic kidney disease: implications for the patho physiology of atherosclerosis. JAT. 2013;20(2):123–133.
   Google Scholar
• Bajaj A, Xie D, Cedillo-Couvert E, CRIC Study Investigators, et al. Lipids, apolipoproteins, and risk of atherosclerotic cardiovascular disease in persons with CKD. Am J Kidney Dis. 2019;73(6):827–836.
   PubMed Web of Science ®Google Scholar
• Matsushita K, van der Velde M, Astor BC, et al. ; Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375(9731):2073–2081.
   PubMed Web of Science ®Google Scholar
• Vanholder R, Massy Z, Argiles A, et al.; European Uremic Toxin Work Group. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant. 2005;20(6):1048–1056.
   PubMed Web of Science ®Google Scholar
• Steenkamp R, Rao A, Roderick P. UK Renal Registry 17th annual report: chapter 5 survival and cause of death in UK adult patients on renal replacement therapy in 2013: national and centre-specific analyses. Nephron. 2015;129(s1):99–129.
   PubMedGoogle Scholar
• United States Renal Data System. 2015. USRDS Annual Data Report volume 2: ESRD in the United States.
   Google Scholar
• Wilson PW, Garrison RJ, Castelli WP, et al. Prevalence of coronary heart disease in the Framingham Offspring Study: role of lipoprotein cholesterols. Am J Cardiol. 1980;46(4):649–654.
   PubMed Web of Science ®Google Scholar
• Emerging Risk Factors Collaboration et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009;302:1993–2000.
   PubMed Web of Science ®Google Scholar
• Hager MR, Narla AD, Tannock LR. Dyslipidemia in patients with chronic kidney disease. Rev Endocr Metab Disord. 2017;18(1):29–40.
   PubMed Web of Science ®Google Scholar
• Zheng- Lin B, Ortiz A. Lipid management in chronic kidney disease: systematic review of PCSK9 targeting. Drugs. 2018;78(2):215–229.
   PubMed Web of Science ®Google Scholar
• Lowrie EG, Lew NL. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am. J. Kidney Dis. 1990;15(5):458–482.
   PubMed Web of Science ®Google Scholar
• Baigent C, Landray MJ, Wheeler DC. Misleading associations between cholesterol and vascular outcomes in dialysis patients: the need for randomized trials. Semin Dial. 2007;20(6):498–503.
   PubMed Web of Science ®Google Scholar
• Lo JC, Go AS, Chandra M, et al. GFR, body mass index, and low high-density lipoprotein concentration in adults with and without CKD. Am. J. Kidney Dis. 2007;50(4):552–558.
   PubMed Web of Science ®Google Scholar
• Ganda A, Magnusson M, Yvan-Charvet L, et al. Mild renal dysfunction and metabolites tied to low HDL cholesterol are associated with monocytosis and atherosclerosis. Circulation. 2013;127(9):988–996.
   PubMed Web of Science ®Google Scholar
• Anderson JL, et al. High density lipoprotein (HDL) particles from end-stage renal disease patients are defective in promoting reverse cholesterol transport. Sci. Rep. 2017;7:41481.
   PubMed Web of Science ®Google Scholar
• Mineo C, Deguchi H, Grifn JH, et al. Endothelial and antithrombotic actions of HDL. Circ Res. 2006;98(11):1352–1364.
   PubMed Web of Science ®Google Scholar
• Besler C, Heinrich K, Rohrer L, et.al. Mechanisms underlying adverse efects of HDL on eNOS-activating pathways in patients with coronary artery disease. J Clin Investig. 2011;121(7):2693–26708.
   PubMed Web of Science ®Google Scholar
• Spieker LE, Sudano I, HüRlimann D, et al. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation. 2002;105(12):1399–1402.
   PubMed Web of Science ®Google Scholar
• Barter PJ, Nicholls S, Rye K-A, et al. Antiinfammatory properties of HDL. Circ Res. 2004;95(8):764–772.
   PubMed Web of Science ®Google Scholar
• Navab M, Yu R, Gharavi N, et al. High-density lipoprotein: antioxidant and anti-inflammatory properties. Curr Atheroscler Rep. 2007;9(3):244–248.
   PubMedGoogle Scholar
• Moradi H, Vaziri ND. Molecular mechanisms of disorders of lipid metabolism in chronic kidney disease. Front Biosci. 2018;23:146–161.
   Web of Science ®Google Scholar
• Meyer TW, Walther JL, Pagtalunan ME, et al. The clearance of protein-bound solutes by hemofiltration and hemodiafiltration. Kidney Int. 2005;68(2):867–877.
   PubMed Web of Science ®Google Scholar
• Niwa T. Indoxyl sulfate is a nephro-vascular toxin. J Ren Nutr. 2010;20(5 Suppl):S2–S6.
   PubMed Web of Science ®Google Scholar
• Vanholder R, Bammens B, de Loor H, et al. Warning: the unfortunate end of p-cresol as a uraemic toxin. Nephrol Dial Transplant. 2011;26(5):1464–1467.
   PubMed Web of Science ®Google Scholar
• Banoglu E, Jha GG, King RS. Hepatic microsomal metabolism of indole to indoxyl, a precursor of indoxyl sulfate. Eur J Drug Metab Pharmacokinet. 2001;26(4):235–240.
   PubMed Web of Science ®Google Scholar
• Lin CJ, Liu HL, Pan CF, et al. Indoxyl sulfate predicts cardiovascular disease and renal function deterioration in advanced chronic kidney disease. Arch Med Res. 2012;43(6):451–456.
   PubMed Web of Science ®Google Scholar
• Adijiang A, Goto S, Uramoto S, et al. Indoxyl sulphate promotes aortic calcification with expression of osteoblastspecific proteins in hypertensive rats. Nephrol Dial Transplant. 2008;23(6):1892–1901.
   PubMed Web of Science ®Google Scholar
• Muteliefu G, Enomoto A, Jiang P, et al. Indoxyl sulphate induces oxidative stress and the expression of osteoblast-specific proteins in vascular smooth muscle cells. Nephrol Dial Transplant. 2009;24(7):2051–2058.
   PubMed Web of Science ®Google Scholar
• Lekawanvijit S, Adrahtas A, Kelly DJ, et al. Does indoxyl sulfate, a uraemic toxin, have direct effects on cardiac fibroblasts and myocytes? Eur Heart J. 2010;31(14):1771–1779.
   PubMed Web of Science ®Google Scholar
• Yisireyili M, Shimizu H, Saito S, et al. Indoxyl sulfate promotes cardiac fibrosis with enhanced oxidative stress in hypertensive rats. Life Sci. 2013;92(24-26):1180–1185.
   PubMed Web of Science ®Google Scholar
• Taki K, Tsuruta Y, Niwa T. Indoxyl sulfate and atherosclerotic risk factors in hemodialysis patients. Am J Nephrol. 2007;27(1):30–35.
   PubMed Web of Science ®Google Scholar
• Asai M, Kumakura S, Kikuchi M. Review of the efficacy of AST-120 (KREMEZIN®) on renal function in chronic kidney disease patients. Ren Fail. 2019;41(1):47–56.
   PubMed Web of Science ®Google Scholar
• Ito S, Ohno Y, Tanaka T, et al. Neutrophil/lymphocyte ratio elevation in renal dysfunction is caused by distortion of leukocyte hematopoiesis in bone marrow. Ren Fail. 2019;41(1):284–293.
   PubMed Web of Science ®Google Scholar